Linda Ertl

ChemoCentryx (United States) — United States

Medicine · Health Sciences

13h-index1.2kcitations62works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemokine receptors and signaling(17), Cancer Immunotherapy and Biomarkers(11), Immunotherapy and Immune Responses(8), Monoclonal and Polyclonal Antibodies Research(8), Immune Cell Function and Interaction(8)

Publications61 total

C5aR expression in kidney tubules, macrophages and fibrosis
Journal of Histotechnology·2024· 5 cited
C5aR Expression in Kidney Tubules, Macrophages and Fibrosis
2023Open Access
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
PLoS ONE·2023· 6 citedOpen Access
499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model
Regular and Young Investigator Award Abstracts·2022· 1 citedOpen Access
Kidney C5aR Is Expressed in Resident Macrophages, Tubular Epithelial Cells, and in Association With Fibrosis
Journal of the American Society of Nephrology·2022
Complement C5a Receptor in Macrophage-Mediated Renal Inflammation and Fibrosis in Lupus Nephritis
Journal of the American Society of Nephrology·2021
Abstract 1274: CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
Cancer Research·2021
Therapeutic Benefit of CCR2 Antagonism in a Model of Diabetic Nephropathy Suggests a Mechanism of Action Distinct from Nrf2 Activation
Journal of the American Society of Nephrology·2020
Abstract 5693: Anti-tumor effect of orally available small molecule PD-L1 inhibitors in a murine model of colon adenocarcinoma
Cancer Research·2020· 2 cited
P0973ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY
Nephrology Dialysis Transplantation·2020
P0336INHIBITION C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) ON ACTIVATED KIDNEY PARIETAL EPITHELIAL CELLS REVEALS A NEW THERAPEUTIC APPROACH FOR CHRONIC KIDNEY DISEASES
Nephrology Dialysis Transplantation·2020Open Access
Antagonists of chemokine receptor CCR9 synergize with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis
The Journal of Immunology·2020
Abstract B26: Tumor reduction by a small molecule human PD-1/PD-L1 inhibitor in a melanoma/PBMC co-implantation model
Cancer Immunology Research·2020· 2 cited
Abstract B08: C-C chemokine receptor 4 (CCR4) antagonism enhances the effectiveness of checkpoint Inhibition in mouse tumor models
Cancer Immunology Research·2020
P037 Antagonism of chemokine receptor CCR9 synergises with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis
Journal of Crohn s and Colitis·2020Open Access
CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood
The Journal of Immunology·2019· 26 citedOpen Access
FP017Critical Equilibrium between CCL2 Secretion and Its Constitutive Re-Uptake by CCR2: An Elegant Mechanism for Regulating CCL2 Levels in the Blood
Nephrology Dialysis Transplantation·2019
FP240CCR2 INHIBITION IMPROVES RENAL FUNCTION IN MURINE MODELS OF CHRONIC KIDNEY DISEASE
Nephrology Dialysis Transplantation·2019
Targeting Chemokine Receptors CCR6 and CXCR2 in A Murine Model Of IL-36a-Induced Pustular Psoriasis
The Journal of Immunology·2019
725 Targeting chemokine receptors CCR6 and CXCR2 in a murine model of IL-36α-induced pustular psoriasis.
Journal of Investigative Dermatology·2019· 1 cited
page 1 of 4Next →

Frequent Co-authors

Thomas J. Schall(45), Israel Charo(26), Penglie Zhang(25), Ton Dang(22), Karen Ebsworth(21), Rajinder Singh(21), James J. Campbell(21), Zhenhua Miao(14), Simon Yau(14), Jeffrey McMahon(13), Juan C. Jaén(12), Jay P. Powers(11), Matthew J. Walters(10), Bin Zhao(10), Dale Newland(10), Vicky Chhina(10), Trageen Baumgart(9), Yibin Zeng(9), Alice Kumamoto(9), Daniel J. Dairaghi(8)